Source: DGNews  |  Posted 9 years ago

By Charlene Laino

SAN ANTONIO, TX -- December 12, 2002 -- Fulvestrant may be effective in the treatment of postmenopausal women with advanced breast cancer that progresses despite intervention with aromatase inhibitor therapy, preliminary results of a new study suggest.

In a phase II, open-label, multicentre, noncomparative study of postmenopausal women with advanced breast cancer that did not respond to endocrine treatment, a clinical benefit was observed in 34 percent of eligible patients treated with fulvestrant, reported Lucien Perey, MD, of the Centre Pluridisciplinaire d'Oncologie in Lausanne, Switzerland.

Dr. Perey presented the data here on behalf of the Swiss Group for Clinical Cancer Research (SAKK) on December 11th at a poster session during the 25th Annual San Antonio Breast Cancer Symposium.

Fulvestrant (Faslodex